What Does CIN Mean? Cervical Grades Explained

CIN stands for cervical intraepithelial neoplasia, a term pathologists use to describe abnormal cell changes found in the lining of the cervix. It is not cancer, but depending on the grade, it can be a precursor to cervical cancer if left untreated. The grading system runs from CIN 1 (mild changes) through CIN 2 (moderate) to CIN 3 (severe), and each grade carries a different likelihood of resolving on its own versus progressing. Understanding what your CIN grade means is the first step toward knowing what to expect and what decisions you may face.

The Three CIN Grades

When a pathologist examines a tissue sample from your cervix under a microscope, CIN grading tells them how much of the surface lining shows abnormal cells. The cervical lining has layers of flat cells stacked on top of each other, and the grades reflect how deeply those layers are affected.

CIN 1: Abnormal cells are limited to roughly the lower third of the lining. This is considered a low-grade change and is the most common finding after an abnormal screening test.
CIN 2: Abnormal cells extend into the lower two-thirds of the lining. This sits at the border between low-grade and high-grade, which is why management of CIN 2 is often the trickiest clinical decision.
CIN 3: Abnormal cells occupy most or all of the lining’s thickness but have not broken through the basement membrane into deeper tissue. Once cells break through that membrane, it is no longer CIN; it is invasive cancer.

You will sometimes see CIN 2 and CIN 3 grouped together under the label “high-grade squamous intraepithelial lesion” (HSIL). That grouping exists because the two grades behave more similarly to each other than either does to CIN 1, and distinguishing them under a microscope can be genuinely difficult. Studies of pathologist agreement on CIN grading have found generally poor consistency between reviewers, with average agreement scores well below what you would hope for in a definitive diagnosis.¹ That imprecision is one reason additional tools like biomarker staining have become important for borderline cases.

Where CIN Develops and Why

Nearly all CIN originates in a specific area of the cervix called the transformation zone. This is where one type of surface cell is continuously converting into another type, and that active remodeling makes the area especially vulnerable to infection and abnormal growth.² Human papillomavirus, or HPV, takes advantage of this vulnerability. Persistent infection with certain high-risk HPV types is the underlying cause of virtually all CIN.

High-risk HPV strains produce two proteins that interfere with your cells’ built-in defenses against uncontrolled growth. One protein promotes the destruction of p53, a key tumor-suppressor molecule, while the other disrupts a separate growth-control pathway.³ With both brakes disabled, infected cells can start dividing abnormally. Whether that process stops at CIN 1 and reverses, or continues climbing the grades, depends on factors including the specific HPV type involved, your immune response, and certain lifestyle exposures.

Screening Terminology Versus Biopsy Results

One of the most confusing parts of a CIN diagnosis is that the terminology on your screening result (a Pap smear or HPV test) does not use the same language as the biopsy result. The screening side uses terms like LSIL (low-grade squamous intraepithelial lesion) and HSIL (high-grade squamous intraepithelial lesion), which describe what cells look like when scraped from the surface. CIN grading, on the other hand, comes from a biopsy, where a pathologist examines actual tissue architecture. The two systems overlap but are not interchangeable.

An LSIL result on a Pap smear often corresponds to CIN 1 on biopsy, but not always. Among women who test positive for HPV and have an HSIL Pap result, the five-year risk of having CIN 2 or worse on biopsy is around 50%, whereas for those with an LSIL result the risk is closer to 6%.⁴ The gap between screening impression and biopsy reality is why an abnormal Pap smear does not by itself tell you what CIN grade you have. A biopsy is needed to confirm the grade and guide management.

How Colposcopy and Biopsy Work

If your screening result is abnormal, the next step is usually colposcopy, a procedure where a clinician examines your cervix through a magnifying instrument after applying a dilute acetic acid solution. The acid causes abnormal areas to turn white, making them visible for targeted biopsy.⁵ Clinicians may take multiple small tissue samples from any white-appearing areas they identify.⁶

Those tissue samples go to a pathologist who assigns the CIN grade. In borderline cases, staining for specific biomarkers can help distinguish low-grade from high-grade disease. Two markers commonly used together are p16 and Ki-67, proteins that reflect how aggressively the cells are dividing and whether the HPV-related growth pathway is active. The rate of positive staining for these markers climbs steeply with CIN grade: roughly half of CIN 1 biopsies stain positive, compared with about 80% of CIN 2 and over 90% of CIN 3.⁷ That stepwise increase helps pathologists feel more confident when the tissue alone is ambiguous.⁸

CIN 1 Usually Goes Away on Its Own

If you have been told you have CIN 1, the most likely outcome is that the abnormal cells will clear without any treatment. Studies tracking women with confirmed CIN 1 find that roughly 70% of these lesions regress within 12 months.⁹ In cases where the HPV infection itself clears (as most do within a couple of years), resolution of the tissue changes essentially reaches 100% over four years of follow-up.¹⁰

The standard approach for CIN 1 is therefore watchful waiting: repeat testing at intervals rather than jumping to a procedure. Treatment for CIN 1 is generally reserved for cases that persist for two or more years, or where the clinical picture raises concern for a higher-grade lesion that the initial biopsy may have missed.

CIN 2 and CIN 3 Require Harder Decisions

CIN 2 occupies an awkward middle ground. About half of CIN 2 lesions regress within a year without treatment, which is notably less than CIN 1’s regression rate but still a coin-flip chance of resolving spontaneously.⁹ Current guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP) allow observation as an alternative to immediate treatment for CIN 2 when the patient is concerned about the effects of excision on a future pregnancy, provided the transformation zone is fully visible and there is no evidence of worse disease in the cervical canal.¹¹ Observation in this context means colposcopy and HPV-based testing every six months for up to two years.

CIN 3 is treated rather than watched. The long-term data here are sobering: among women whose CIN 3 was not adequately treated, the cumulative risk of developing invasive cervical cancer reached about 31% over 30 years.¹² That same study found the risk dropped below 1% in women who received standard treatment. Progression is slow, with a median estimated time from CIN 2/3 to cancer of over two decades, but without treatment the trajectory is clear enough that waiting is not considered a safe option for CIN 3.¹³

Treatment Options for High-Grade CIN

When treatment is recommended, the most common procedure is a loop electrosurgical excision, often called LEEP (or LLETZ in some countries). A thin wire loop carrying an electrical current removes the abnormal area. It is typically done under local anesthesia in an office setting and takes only a few minutes. Cold-knife conization, a more traditional surgical excision performed under general or regional anesthesia, removes a slightly larger cone-shaped piece of tissue. A meta-analysis comparing the two found that positive margins (where abnormal cells extend to the edge of the removed tissue, raising concern that not everything was cleared) occurred in roughly 22% of LEEP cases versus 13% of cold-knife conizations, though the difference was not statistically significant overall.¹⁴

Ablative methods, which destroy tissue with heat or freezing rather than removing it, are also used, particularly in resource-limited settings. A randomized trial comparing cryotherapy and thermal ablation found cure rates for CIN 1 or worse of about 74% and 81%, respectively.¹⁵ Ablation is generally not preferred for high-grade lesions when excision is available, because excision provides a tissue specimen that can be examined for margin status and confirm the full extent of disease. In a study of thermal ablation for CIN 2/3 among women living with HIV, treatment failure was about 34%, with failure rates higher for CIN 3 than CIN 2.¹⁶

Does Treatment Affect Future Pregnancies

This is one of the first things people ask after hearing they need a LEEP, and the picture is more reassuring than it used to be. A systematic review and meta-analysis found that LEEP was associated with a higher rate of preterm birth compared with women in the general population. However, when LEEP patients were compared specifically to women who had also been diagnosed with cervical dysplasia but did not have a procedure, the increased risk essentially disappeared.¹⁷ That finding suggests the underlying condition and its associated risk factors, rather than the procedure itself, may explain much of the apparent risk.

Research on tissue-preserving LEEP techniques (removing less cervical tissue than traditional approaches) found no increase in preterm birth or miscarriage, though there was a higher rate of premature rupture of membranes at term.¹⁸ Cone height matters here: data from a large cohort found that increasing the height of tissue removed was directly associated with increasing risk of preterm delivery and premature membrane rupture.¹⁹ If future pregnancy is on your mind, discussing a tissue-conserving approach with your clinician is worth doing.

Follow-Up After Treatment

Treatment is not the end of the story. Recurrence of high-grade CIN occurs in roughly 8 to 10% of treated patients over several years of follow-up.²⁰ The current approach to post-treatment surveillance uses HPV testing, with or without cytology, to detect recurrence early. A negative HPV test six months after treatment is a strong indicator that the disease has been fully cleared, and ongoing HPV-negative results allow a gradual return to routine screening intervals.²¹

HPV testing alone appears to perform comparably to combined HPV and cytology testing (co-testing) for detecting recurrence. In one large register-based study, the negative predictive value for excluding high-grade recurrence was 97% for HPV testing alone versus 98% for co-testing, a gap that was not statistically significant.²⁰ The message for patients is straightforward: keep your follow-up appointments, and a clean HPV test after treatment is a reliable signal that things are going well.

Smoking and CIN Progression

HPV is the necessary ingredient for CIN, but it is not the only factor influencing what happens next. Smoking is one of the best-studied cofactors. A longitudinal study of young women found that smoking ten or more cigarettes per day roughly doubled the risk of developing high-grade CIN, even after accounting for HPV status.²² The mechanism appears to involve the immune system’s ability to clear the virus: ever-smokers maintained HPV infections for longer and were less likely to clear high-risk HPV strains than women who had never smoked.²³

This is one of the few modifiable risk factors in the CIN picture. If you are being monitored for CIN 1 or CIN 2 and hoping for spontaneous regression, quitting smoking is one of the more impactful things you can do to help that process along.

HPV Vaccination After a LEEP

Getting an HPV vaccine after you already have CIN might sound like locking the door after the break-in, but accumulating evidence suggests it helps prevent recurrence. One study found that women who received the HPV vaccine after a LEEP for high-grade CIN had a recurrence rate of about 2.5%, compared with roughly 7% in women who were not vaccinated. For recurrence involving the specific HPV types targeted by the vaccine, the gap was even wider.²⁴ Another institutional study reported similar findings: vaccination after LEEP was an independent protective factor against needing a second procedure.²⁵

The vaccine does not treat existing HPV infection, but it can prevent reinfection with the same or different high-risk strains. If you are undergoing treatment for CIN and have not been vaccinated, it is worth discussing with your provider.

Why Some CIN 2 and CIN 3 Lesions Regress Spontaneously

The fact that even some high-grade lesions resolve without treatment has puzzled researchers for years. Part of the explanation lies in the local immune environment of the cervix. Studies comparing the immune cells surrounding regressing CIN 2/3 lesions with those around persistent ones have found meaningful differences. Lesions that went on to regress had higher numbers of certain immune cells in the surrounding tissue and more favorable ratios of attacking-to-suppressing immune populations.²⁶ The specific HPV type matters too: HPV-16 lesions appear less likely to regress than those caused by other high-risk types.

This research is still far from the point where a blood test or biopsy stain could reliably tell you whether your CIN 2 will go away on its own. But it is one reason the guidelines now allow careful observation of CIN 2 in certain situations rather than mandating immediate treatment for everyone.

The Emotional Side of a CIN Diagnosis

Something that rarely gets enough attention in clinical discussions is the psychological impact of being told you have precancerous cells. A systematic review found that receiving a CIN diagnosis and undergoing treatment were associated with worse psychological outcomes compared to receiving a normal screening result, including heightened anxiety, distress, and concerns about fertility and sexual health.²⁷ The word “neoplasia” sounds alarming, and the connection to a sexually transmitted virus can carry its own weight of stigma and self-blame.

The review also noted that the psychological impact tended to decrease over time, particularly once follow-up testing came back normal. If you are navigating a CIN diagnosis and finding the uncertainty stressful, that response is common and well-documented. Understanding that most CIN, especially CIN 1, resolves on its own, and that even higher grades are highly treatable, can help put the diagnosis in perspective. Asking your clinician to walk you through the specific numbers for your grade and HPV status is often more calming than attempting to interpret things on your own.

Risk-Based Management and What It Means for You

The 2019 ASCCP guidelines shifted away from a one-size-fits-all approach and toward risk-based management, meaning that your clinical history, HPV test results, and current findings all feed into an estimate of your personal risk, and that risk level determines what happens next.²⁸ Two patients with the same Pap result may get different recommendations depending on their prior screening history and HPV status.

In practice, this means that if you have had consistently normal HPV tests in the past and then get a mildly abnormal Pap result, your estimated risk of harboring high-grade CIN is lower than someone with the same Pap result who has never been tested for HPV. The management tables use those accumulated risk estimates to recommend anything from repeating the test in a year to proceeding directly to colposcopy or treatment. If your clinician recommends a plan that seems either more aggressive or more conservative than you expected, ask about where your risk estimate falls. The framework is designed to balance catching disease early against overtreating findings that would likely resolve on their own.